Convergence Financial’s Belite Bio BLTE Stock Holding History

Convergence Financial’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,968	Closed	-$473K	–	276
2026 Q1	$473K	Buy	+2,968	New	+$499K	0.05%	149

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Convergence Financial's BLTE Position: Q2 2026 in Review

Convergence Financial sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 2,968 shares — an estimated $473K sold.

Convergence Financial first reported a position in BLTE in Q1 2026 and held it in 1 quarter. The position peaked at $473K in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

Convergence Financial reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
Convergence Financial sold 2,968 Belite Bio shares in Q2 2026, an estimated $473K.
Convergence Financial first reported a position in Belite Bio in Q1 2026 and held it in 1 quarter.
Convergence Financial's Belite Bio position peaked at $473K in Q1 2026.
81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Convergence Financial's 13F filing for Q2 2026, filed 5 Aug 2026.